Biotech

Twist Bioscience

Twist Bioscience secures $120M Series D for biotech innovation

$120M
Total Raised
Series D
Latest Round
2013
Founded
500+
Employees
South San Francisco, CA
4 min read

Quick Facts

Valuation
$1.5B
Latest Round Size
$120M
Latest Round Date
September 2025

Twist Bioscience Secures $120M to Transform Biotech Industry

Twist Bioscience has successfully raised $120M in Series D funding, marking a significant milestone in the company's growth journey. This latest investment brings the company's total funding to $350M and establishes a $1.5B valuation.

Company Background

Founded in 2013 and headquartered in South San Francisco, CA, Twist Bioscience has emerged as a leader in Synthetic biology company manufacturing DNA sequences. With a team of 500+ dedicated professionals, the company has built a reputation for innovation and customer-centric solutions.

Business Model Innovation

Biotechnology platform providing synthetic DNA manufacturing for research and applications

The company's approach has resonated strongly with customers and investors alike, demonstrating sustainable growth and market validation across multiple metrics.

Market Opportunity

The market for Twist Bioscience's solutions represents a significant opportunity, with increasing demand driven by digital transformation trends and evolving customer expectations.

Industry Dynamics

  • Digital Adoption: Accelerating shift toward digital-first solutions
  • Customer Expectations: Rising demand for seamless, efficient experiences
  • Market Consolidation: Opportunity for technology leaders to capture market share
  • Innovation Imperative: Need for continuous technological advancement

Funding Round Analysis

This Series D represents more than just capital injection—it's a strategic partnership that will accelerate Twist Bioscience's mission and expand its market reach.

Strategic Value

The funding provides Twist Bioscience with the resources necessary to:

  1. Scale Operations: Expanding team and operational capacity
  2. Enhance Technology: Investing in platform capabilities and innovation
  3. Market Expansion: Growing presence in new geographic and vertical markets
  4. Customer Success: Improving customer experience and support capabilities

Investor Confidence

The successful completion of this funding round demonstrates strong investor confidence in Twist Bioscience's vision, execution capabilities, and market opportunity.

Technology Platform

Twist Bioscience has built a robust technology platform that serves as the foundation for its competitive advantage and growth strategy.

Platform Capabilities

  • Scalable Architecture: Built for enterprise-grade performance and reliability
  • Integration Ecosystem: Seamless connectivity with existing business systems
  • Data Analytics: Advanced insights and reporting capabilities
  • Security & Compliance: Enterprise-grade security and regulatory compliance

Innovation Focus

The company continues to invest heavily in research and development, ensuring its platform remains at the forefront of technological advancement and industry best practices.

Competitive Positioning

Twist Bioscience has established a strong competitive position through its focus on innovation, customer success, and market expertise.

Competitive Advantages

  • Market Leadership: Strong position in target market segments
  • Technology Differentiation: Unique capabilities and innovative features
  • Customer Relationships: Strong customer satisfaction and retention rates
  • Team Expertise: Deep industry knowledge and technical capabilities

Growth Strategy

With this latest funding, Twist Bioscience is well-positioned to execute on an ambitious growth strategy that includes market expansion, product development, and strategic partnerships.

Strategic Priorities

  1. Product Innovation: Continued investment in platform enhancement and new features
  2. Market Penetration: Expanding customer base within existing markets
  3. Geographic Expansion: Entering new geographic markets and regions
  4. Partnership Development: Strategic alliances and ecosystem partnerships

Operational Excellence

The company plans to invest in operational infrastructure and capabilities to support sustained growth while maintaining high levels of customer satisfaction and service quality.

Financial Performance

While specific financial metrics are not disclosed, the company's ability to raise $120M at a $1.5B valuation indicates strong financial performance and growth trajectory.

Key Metrics

  • Revenue Growth: Demonstrating consistent growth in recurring revenue
  • Customer Acquisition: Expanding customer base across target segments
  • Market Share: Growing presence in addressable market
  • Unit Economics: Healthy customer acquisition costs and lifetime value metrics

Future Outlook

The successful completion of this funding round positions Twist Bioscience for continued growth and market leadership. The company's focus on innovation, customer success, and operational excellence provides a strong foundation for future expansion.

Long-term Vision

Twist Bioscience is committed to transforming the biotech industry through technology innovation and customer-centric solutions. The company's long-term vision includes becoming the leading platform in its market category while expanding into adjacent markets and geographies.

Market Impact

As Twist Bioscience continues to grow and innovate, the company is positioned to drive significant positive impact across its industry, helping customers achieve better outcomes while creating value for stakeholders.

This funding round represents an important milestone in Twist Bioscience's journey, providing the resources and strategic support needed to accelerate growth and achieve its ambitious goals.

Key Investors

Greylock Partners
Existing Investor
Venture capital firm specializing in early-stage technology investments
Founders Fund
Co-Investor
San Francisco-based venture capital fund investing in technology companies
Kleiner Perkins
Lead Investor
Prominent venture capital firm focusing on early-stage technology companies

About the Author

Anna Rodriguez
Anna Rodriguez
AI and machine learning journalist focusing on enterprise AI implementations